Low Frequency of CD161 + CD4 + T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment

@inproceedings{Lee2016LowFO,
  title={Low Frequency of CD161 + CD4 + T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment},
  author={Sung-Eun Lee and Ji-Young Lim and Da-Bin Ryu and Tae Woo Kim and Sung Soo Park and Young-Woo Jeon and Jae-Ho Yoon and B. Cho and Ki-Seong Eom and Yoo-Jin Kim and Hee-Je Kim and Seok Lee and Seok-Goo Cho and Dong-wook Kim and Jong-Wook Lee and Woo-Sung Min and Chang-Ki Min},
  year={2016}
}
Background Although the combination of lenalidomide and low-dose dexamethasone (Len-dex) is known to preserve the efficacy with reduced toxicity than lenalidomide plus high-dose dexamethasone (Len-Dex) in patients with refractory/relapsed multiple myeloma (RRMM), infection is still a leading toxicity. Moreover, the patterns and risks for infection in patients with RRMM during Len-dex treatment remain unclear and there is a need to identify contributing factors associated with increased risk for… CONTINUE READING